PT - JOURNAL ARTICLE AU - Atassi, Giancarlo AU - Scheetz, Marc AU - Nozick, Sophia AU - Rhodes, Nathaniel J. AU - Murphy-Belcaster, Megan AU - Murphy, Katherine R AU - Ozer, Egon A. AU - Hauser, Alan R. TI - Genomics of Aminoglycoside Resistance in <em>Pseudomonas aeruginosa</em> Bloodstream Infections at a United States Academic Hospital AID - 10.1101/2021.01.15.21249897 DP - 2021 Jan 01 TA - medRxiv PG - 2021.01.15.21249897 4099 - http://medrxiv.org/content/early/2021/01/20/2021.01.15.21249897.short 4100 - http://medrxiv.org/content/early/2021/01/20/2021.01.15.21249897.full AB - Pseudomonas aeruginosa is a frequent cause of antibiotic-resistant infections. Although P. aeruginosa is intrinsically resistant to many antimicrobial agents, aminoglycosides are active against this organism in the absence of acquired resistance determinants and mutations. However, genes encoding aminoglycoside modifying enzymes (AMEs) are found in many strains that are resistant to these agents. We examined the prevalence of phenotypic resistance to the commonly used aminoglycosides gentamicin, tobramycin, and amikacin in a collection of 227 P. aeruginosa bloodstream isolates collected over two decades from a single U.S. academic medical institution. Resistance to these antibiotics was relatively stable over this time period. High-risk clones ST111 and ST298 were initially common but decreased in frequency over time. Whole genome sequencing identified relatively few AME genes in this collection compared to the published literature; only 14% of isolates contained an AME gene other than the ubiquitous aph(3’)-IIb. Of those present, only ant(2”)-Ia was associated with phenotypic resistance to gentamicin or to tobramycin. One extensively drug-resistant strain, PS1871, contained 5 AME genes, most of which were part of clusters of antibiotic resistance genes embedded within transposable elements. These findings suggest that AME genes play a relatively minor role in aminoglycoside resistance at our institution but that multidrug-resistant strains remain a problem.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe project was funded by the National Institutes of Health: R01AI118257, U19AI135964, K24AI04831, and R21AI129167 (all to A.R.H.).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Northwestern University IRBAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data used to generate the tables and figures for this manuscript are available upon request.